Kala Pharmaceuticals Inc (KALA) Expected to Announce Earnings of -$0.58 Per Share

Wall Street brokerages expect that Kala Pharmaceuticals Inc (NASDAQ:KALA) will report earnings per share of ($0.58) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Kala Pharmaceuticals’ earnings. The highest EPS estimate is ($0.43) and the lowest is ($0.63). Kala Pharmaceuticals posted earnings per share of ($0.56) in the same quarter last year, which would indicate a negative year-over-year growth rate of 3.6%. The company is scheduled to report its next earnings report on Tuesday, November 6th.

On average, analysts expect that Kala Pharmaceuticals will report full year earnings of ($2.19) per share for the current year, with EPS estimates ranging from ($2.38) to ($1.72). For the next financial year, analysts anticipate that the business will report earnings of ($2.67) per share, with EPS estimates ranging from ($3.68) to ($1.21). Zacks’ EPS averages are an average based on a survey of sell-side research firms that cover Kala Pharmaceuticals.

Kala Pharmaceuticals (NASDAQ:KALA) last released its quarterly earnings data on Thursday, August 9th. The company reported ($0.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.10).

A number of equities analysts have recently commented on the company. HC Wainwright set a $37.00 price objective on Kala Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, September 10th. Wells Fargo & Co restated a “buy” rating on shares of Kala Pharmaceuticals in a report on Thursday, August 23rd. BidaskClub downgraded Kala Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, July 12th. Wedbush reiterated an “outperform” rating and set a $47.00 target price on shares of Kala Pharmaceuticals in a report on Wednesday, June 20th. Finally, Zacks Investment Research upgraded Kala Pharmaceuticals from a “hold” rating to a “buy” rating and set a $14.00 target price on the stock in a report on Wednesday, July 18th. Two analysts have rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $31.20.

Kala Pharmaceuticals stock opened at $10.38 on Friday. The company has a debt-to-equity ratio of 0.27, a current ratio of 9.79 and a quick ratio of 9.79. Kala Pharmaceuticals has a 12 month low of $10.34 and a 12 month high of $24.46.

Large investors have recently made changes to their positions in the stock. MetLife Investment Advisors LLC purchased a new stake in shares of Kala Pharmaceuticals during the 1st quarter valued at about $119,000. American International Group Inc. raised its holdings in shares of Kala Pharmaceuticals by 86.6% during the 1st quarter. American International Group Inc. now owns 9,119 shares of the company’s stock valued at $144,000 after buying an additional 4,232 shares during the period. Rhumbline Advisers purchased a new stake in shares of Kala Pharmaceuticals during the 2nd quarter valued at about $148,000. Paloma Partners Management Co purchased a new stake in shares of Kala Pharmaceuticals during the 2nd quarter valued at about $152,000. Finally, The Manufacturers Life Insurance Company raised its holdings in shares of Kala Pharmaceuticals by 489.8% during the 1st quarter. The Manufacturers Life Insurance Company now owns 11,778 shares of the company’s stock valued at $186,000 after buying an additional 9,781 shares during the period. Institutional investors and hedge funds own 72.19% of the company’s stock.

About Kala Pharmaceuticals

Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. Its product candidates include KPI-121 1.0%, which has completed Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; INVELTYS that has completed Phase III clinical trials for the temporary relief of the signs and symptoms of dry eye disease; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases.

Featured Article: Outstanding Shares, Buying and Selling Stocks

Get a free copy of the Zacks research report on Kala Pharmaceuticals (KALA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Kala Pharmaceuticals (NASDAQ:KALA)

Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply